Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | March 18, 2024 | March 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date March 18, 2024 · Filed March 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,299 |
Ending reported balance
After 2024-03-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-18 · Exercise / conversion · Acquired 10,000 · Balance 40,809 Row 2 · 2024-03-18 · Tax withholding · Disposed 9,510 · Balance 31,299 |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $79.70 · Expires 2024-03-18 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-18 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: Reflects the number of options outstanding after the transaction from this specific stock option grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of options outstanding after the transaction from this specific stock option grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2024 Filed Mar 20, 2024 21:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $79.70 | $0.00 |
DisclosureSEC source: 0001048477-24-000052 · wk-form4_1710969202.xml · derivative · entry 3 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transaction from this specific stock option grant. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 9,510 | $83.81 | $797,033.10 |
DisclosureSEC source: 0001048477-24-000052 · wk-form4_1710969202.xml · nonDerivative · entry 2 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,299 Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:13 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $79.70 | $797,000.00 |
DisclosureSEC source: 0001048477-24-000052 · wk-form4_1710969202.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2023 Filed May 24, 2023 22:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031978 · doc4.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,809 F1 · price: Restricted stock units granted on May 23, 2023. Price not applicable. Read SEC document |
| May 24, 2022 Filed May 27, 2022 01:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011802 · doc1.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,619 F1 · price: Restricted stock units granted on May 24, 2022. Price not applicable. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 100 | $78.37 | $7,837.00 |
DisclosureSEC source: 0001567619-22-006092 · doc1.xml · nonDerivative · entry 6 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,639 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 122 | $78.36 | $9,559.92 |
DisclosureSEC source: 0001567619-22-006092 · doc1.xml · nonDerivative · entry 5 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,739 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 100 | $78.35 | $7,835.20 |
DisclosureSEC source: 0001567619-22-006092 · doc1.xml · nonDerivative · entry 4 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,861 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 214 | $78.35 | $16,766.90 |
DisclosureSEC source: 0001567619-22-006092 · doc1.xml · nonDerivative · entry 3 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,961 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 45 | $78.34 | $3,525.30 |
DisclosureSEC source: 0001567619-22-006092 · doc1.xml · nonDerivative · entry 2 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,175 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,815 | $78.33 | $455,488.95 |
DisclosureSEC source: 0001567619-22-006092 · doc1.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,220 Read SEC document |
| May 25, 2021 Filed May 28, 2021 00:44 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011326 · doc1.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,035 F1 · price: Restricted stock units granted on May 25, 2021. Price not applicable. Read SEC document |
| May 27, 2020 Filed May 29, 2020 22:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011375 · doc1.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,915 F1 · price: Restricted stock units granted on May 27, 2020. Price not applicable. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012969 · doc1.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,615 F1 · price: Restricted stock units granted on June 4, 2019. Price not applicable. Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 01:18 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-027801 · doc1.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,185 F1 · price: Restricted stock units granted on June 5, 2018. Price not applicable. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (right to buy) Common Stock · Derivative | 4,910 | $0.00 Strike: $89.60 | $0.00 |
DisclosureSEC source: 0001140361-17-024510 · doc1.xml · derivative · entry 2 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2027-06-05 F2 · derivative.exercise_date: Option grant vests in full on June 6, 2018. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024510 · doc1.xml · nonDerivative · entry 1 Slamon Dennis · CIK 0001603265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,885 F1 · price: Restricted stock units granted on June 6, 2017. Price not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.